Developer docs
API playgroundTry for free, no card

Search company profiles

Lincoln Park Capital Fund

Full company profile

uuid0008kuc

Namestring
Lincoln Park Capital Fund
Legal namestring
Lincoln Park Capital
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Lincoln Park Capital Fund is a Chicago-based private investment group operating across three stated strategies: public markets, private equity and venture capital, and real estate. Founded circa 2013 and operating with a small team of 1–10 employees, the firm positions itself as a multi-strategy capital provider with stated global reach spanning more than 17 countries, suggesting cross-border deal sourcing or co-investment activity rather than a purely domestic footprint.

The firm’s most visible recent activity centers on structured equity financings for public issuers via share purchase agreements (SPAs). In April 2026 it entered a $25M SPA with Vaxart, and in May 2026 it entered a $50M SPA with Veraxa Biotech, indicating an emerging focus on clinical-stage life sciences counterparties needing committed equity capital lines. Leadership is concentrated among co-founders Richard C. Vogel (President), Jonathan I. Cope, Joshua B. Scheinfeld, Robert A. Garcia (CFO), and Frederic J. Salchli (CTO and VP), who together appear to run both investment and operational functions.

Economically, the firm combines the economics of a capital allocator — returns driven by equity appreciation, SPA economics, and management or performance fees on undisclosed AUM — with the operating profile of a small platform. No revenue, AUM, or fund-size disclosures are available in the supplied material, and the firm does not disclose AI/ML capabilities, proprietary technology products, or differentiated research infrastructure; its moat rests on transaction track record, counterparty relationships, and the regulatory infrastructure required to operate a multi-strategy investment business.

Short descriptiontext

Chicago-based private investment group operating across public markets, PE/VC, and real estate; founded circa 2013 with a 1–10 person team and a recent visible focus on biotech share purchase agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
equity financing, share purchase agreements, private equity investing, venture capital funding, asset management services
Industry2 codes
1Small-Cap Equity (Active)
CodeFSAAAIACPrimaryYes
2Growth Equity Fund-of-Funds
CodeFSANAGAEPrimaryNo
NAICS code2 codes
  • Other Financial Investment Activities5239
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Equity Financing / Asset Management
Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Lincoln Park Capital Fund is a Chicago-based investment group that provides flexible equity financing to public and private companies through share purchase agreements (SPAs). The fund deploys capital across three investment types: Public Markets, Private Equity/Venture Capital, and Real Estate, typically structured as 24-month facilities allowing portfolio companies to sell common stock at prevailing market prices without warrants or other dilutive instruments.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lincoln Park Capital Fund is a Chicago-based investment group offering three core investment products: Public Markets Investment, Private Equity/Venture Capital, and Real Estate Investment. The fund provides equity financing facilities and share purchase agreements to client companies, typically structured as 24-month facilities allowing companies to sell common stock at prevailing market prices. The company operates across multiple global time zones with investments in Canada, US states (California, Washington, Minnesota, New York, Texas, Florida, Pennsylvania, New Jersey, Massachusetts, Maryland), United Kingdom, Greece, Israel, India, Australia, and Switzerland.

Product and service1 record
1Public Markets Investment
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest dedicated ELOC / committed equity facility providers to small-cap public companies, including biotech. Closest direct peer to Lincoln Park's SPA product given overlapping issuer base, structure (multi-tranche equity lines), and use of discount-to-market pricing.

TypeDirect peer
Description

Direct ELOC provider to small-cap public issuers, frequently transacting with clinical-stage biotech and similar high-dilution candidates. Directly comparable to LPC on product structure, target issuer size, and sector focus.

TypeDirect peer
Description

Long-standing small-cap equity investor that regularly participates in ELOC and registered direct financings for biotech and tech issuers. Comparable to LPC in deal size, issuer type, and use of structured equity purchases.

4GEM Global Yield Fund
TypeDirect peer
Description

Provides structured equity facilities (share subscription facilities) to small-cap and mid-cap public companies globally, with terms similar to Lincoln Park's SPAs (multi-year, market-price drawdowns). Direct competitive overlap on the ELOC product.

TypeDirect peer
Description

Specialist provider of equity lines and convertible financings to small-cap issuers, including biotech and consumer companies. Comparable deal economics (discount pricing, periodic drawdowns) and client profile to LPC.

TypeDirect peer
Description

Provides structured equity financings and ELOCs to small-cap public companies. Operates in the same niche as Lincoln Park with similar transaction sizing and sector exposure.

TypeDirect peer
Description

Alternative-asset manager that participates in structured equity and ELOC-style financings for small-cap public companies. Comparable transaction structures and target issuer profile.

TypeDirect peer
Description

Multi-strategy fund manager with active participation in small-cap equity financings, including ELOCs and registered direct offerings. Overlaps with Lincoln Park on deal type, size, and biotech-sector exposure.

TypeDirect peer
Description

Investment bank focused on small- and micro-cap issuers that also arranges equity lines and committed equity financings. Direct competitive overlap with LPC's biotech and small-cap clientele.

TypeBroad incumbent
Description

Full-service broker-dealer and investment bank for small- and mid-cap companies with an active ELOC / committed equity financing practice. Broader product suite than LPC but directly competes for the same issuer mandates.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment44 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lincoln Park Capital Fund

Equity Financing / Asset Managementlincolnparkcapital.com

Chicago-based private investment group operating across public markets, PE/VC, and real estate; founded circa 2013 with a 1–10 person team and a recent visible focus on biotech share purchase agreements.

What Lincoln Park Capital Fund does

Lincoln Park Capital Fund is a Chicago-based private investment group operating across three stated strategies: public markets, private equity and venture capital, and real estate. Founded circa 2013 and operating with a small team of 1–10 employees, the firm positions itself as a multi-strategy capital provider with stated global reach spanning more than 17 countries, suggesting cross-border deal sourcing or co-investment activity rather than a purely domestic footprint.

The firm’s most visible recent activity centers on structured equity financings for public issuers via share purchase agreements (SPAs). In April 2026 it entered a $25M SPA with Vaxart, and in May 2026 it entered a $50M SPA with Veraxa Biotech, indicating an emerging focus on clinical-stage life sciences counterparties needing committed equity capital lines. Leadership is concentrated among co-founders Richard C. Vogel (President), Jonathan I. Cope, Joshua B. Scheinfeld, Robert A. Garcia (CFO), and Frederic J. Salchli (CTO and VP), who together appear to run both investment and operational functions.

Economically, the firm combines the economics of a capital allocator — returns driven by equity appreciation, SPA economics, and management or performance fees on undisclosed AUM — with the operating profile of a small platform. No revenue, AUM, or fund-size disclosures are available in the supplied material, and the firm does not disclose AI/ML capabilities, proprietary technology products, or differentiated research infrastructure; its moat rests on transaction track record, counterparty relationships, and the regulatory infrastructure required to operate a multi-strategy investment business.

Lincoln Park Capital Fund firmographics

Firmographics
Name
Lincoln Park Capital Fund
Legal name
Lincoln Park Capital
Website
http://www.lincolnparkcapital.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Chicago-based private investment group operating across public markets, PE/VC, and real estate; founded circa 2013 with a 1–10 person team and a recent visible focus on biotech share purchase agreements.
Ownership category
akta.pro rank

Lincoln Park Capital Fund industry classification

Industry
Product category
Equity Financing / Asset Management
NAICS
Other Financial Investment Activities (5239), Portfolio Management and Investment Advice (523940)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro primary industry
Small-Cap Equity (Active) (FSAAAIAC)
akta.pro secondary industry
Growth Equity Fund-of-Funds (FSANAGAE)

Keywords

  • Equity financing
  • Share purchase agreements
  • Private equity investing
  • Venture capital funding
  • Asset management services

Where Lincoln Park Capital Fund is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lincoln Park Capital Fund business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Lincoln Park Capital Fund product offering

Product offering

Core offering

Lincoln Park Capital Fund is a Chicago-based investment group that provides flexible equity financing to public and private companies through share purchase agreements (SPAs). The fund deploys capital across three investment types: Public Markets, Private Equity/Venture Capital, and Real Estate, typically structured as 24-month facilities allowing portfolio companies to sell common stock at prevailing market prices without warrants or other dilutive instruments.

Product overview

Lincoln Park Capital Fund is a Chicago-based investment group offering three core investment products: Public Markets Investment, Private Equity/Venture Capital, and Real Estate Investment. The fund provides equity financing facilities and share purchase agreements to client companies, typically structured as 24-month facilities allowing companies to sell common stock at prevailing market prices. The company operates across multiple global time zones with investments in Canada, US states (California, Washington, Minnesota, New York, Texas, Florida, Pennsylvania, New Jersey, Massachusetts, Maryland), United Kingdom, Greece, Israel, India, Australia, and Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

  • Public Markets Investment

Companies that use Lincoln Park Capital Fund

Customer profile

Segments2 records

Ideal customer profiles2 records

Lincoln Park Capital Fund technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lincoln Park Capital Fund partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Lincoln Park Capital Fund competitors and assessment

Company assessment

Direct peers

  • Yorkville Advisors: One of the largest dedicated ELOC / committed equity facility providers to small-cap public companies, including biotech. Closest direct peer to Lincoln Park's SPA product given overlapping issuer base, structure (multi-tranche equity lines), and use of discount-to-market pricing.
  • Triton Funds: Direct ELOC provider to small-cap public issuers, frequently transacting with clinical-stage biotech and similar high-dilution candidates. Directly comparable to LPC on product structure, target issuer size, and sector focus.
  • Iroquois Capital: Long-standing small-cap equity investor that regularly participates in ELOC and registered direct financings for biotech and tech issuers. Comparable to LPC in deal size, issuer type, and use of structured equity purchases.
  • GEM Global Yield Fund: Provides structured equity facilities (share subscription facilities) to small-cap and mid-cap public companies globally, with terms similar to Lincoln Park's SPAs (multi-year, market-price drawdowns). Direct competitive overlap on the ELOC product.
  • Oasis Capital: Specialist provider of equity lines and convertible financings to small-cap issuers, including biotech and consumer companies. Comparable deal economics (discount pricing, periodic drawdowns) and client profile to LPC.
  • Southwell Partners: Provides structured equity financings and ELOCs to small-cap public companies. Operates in the same niche as Lincoln Park with similar transaction sizing and sector exposure.
  • K2 Principal Fund: Alternative-asset manager that participates in structured equity and ELOC-style financings for small-cap public companies. Comparable transaction structures and target issuer profile.
  • Anson Funds: Multi-strategy fund manager with active participation in small-cap equity financings, including ELOCs and registered direct offerings. Overlaps with Lincoln Park on deal type, size, and biotech-sector exposure.
  • Ascendiant Capital Markets: Investment bank focused on small- and micro-cap issuers that also arranges equity lines and committed equity financings. Direct competitive overlap with LPC's biotech and small-cap clientele.

Broad incumbents

  • Maxim Group: Full-service broker-dealer and investment bank for small- and mid-cap companies with an active ELOC / committed equity financing practice. Broader product suite than LPC but directly competes for the same issuer mandates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Lincoln Park Capital Fund social profiles

Digital presence

Lincoln Park Capital Fund financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lincoln Park Capital Fund leadership team

Management profile

Number of profiles

Profiles5 records

Lincoln Park Capital Fund funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lincoln Park Capital Fund M&A and investment

M&A and investment

M&A

Investments44 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lincoln Park Capital Fund

What does Lincoln Park Capital Fund do?

Lincoln Park Capital Fund is a Chicago-based investment group that provides flexible equity financing to public and private companies through share purchase agreements (SPAs). The fund deploys capital across three investment types: Public Markets, Private Equity/Venture Capital, and Real Estate, typically structured as 24-month facilities allowing portfolio companies to sell common stock at prevailing market prices without warrants or other dilutive instruments.

Is Lincoln Park Capital Fund a public or private company?

Lincoln Park Capital Fund is a private company. It is classified as unknown and is currently operating.

When was Lincoln Park Capital Fund founded?

Lincoln Park Capital Fund was founded in 2010. It employs 1 to 10 people.

Where is Lincoln Park Capital Fund based?

Lincoln Park Capital Fund is headquartered in Chicago, United States, in the North America region.

Who are Lincoln Park Capital Fund's main competitors?

Direct peers on record are Yorkville Advisors, Triton Funds, Iroquois Capital, GEM Global Yield Fund, Oasis Capital, Southwell Partners, K2 Principal Fund, Anson Funds and Ascendiant Capital Markets. Maxim Group is listed as a broad incumbent.

Does Lincoln Park Capital Fund have an API?

No public API is recorded for Lincoln Park Capital Fund.

What industry is Lincoln Park Capital Fund in?

Lincoln Park Capital Fund's product category is Equity Financing / Asset Management. Its primary akta.pro industry code is FSAAAIAC, Small-Cap Equity (Active), with a secondary code of FSANAGAE, Growth Equity Fund-of-Funds. Its NAICS code is 5239 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessCingulate reported Q2 2026 results with $28.4M cash and a $5.9M net loss, and advanced CMC work for CTx-1301 NDA resubmission. The company plans to resubmit the NDA to the FDA as soon as practicable after completing requested CMC work.FinancialContent Business PageFTC Solar Announces Second Quarter 2026 Financial ResultsFTC Solar reported second quarter 2026 revenue of $26.2 million, representing a 52% sequential increase and 31% year-over-year growth, with the company reaffirming its outlook for 40% annual revenue growth in 2026. The company posted a GAAP net loss of $27.1 million and an adjusted EBITDA loss of $9.8 million, while its contracted backlog stood at approximately $560 million. During the quarter, FTC Solar announced entry into the India market with multiple initial project wins and secured a new 400MW purchase order, while also establishing a $20 million equity line of credit with Lincoln Park Capital.GlobeNewswireFTC Solar Announces Second Quarter 2026 Financial ResultsFTC Solar reported Q2 2026 revenue of $26.2 million, up 52% sequentially and 31% year-over-year. The company reaffirmed its full-year 2026 revenue growth outlook of 40% and expects Q3 growth of about 24%.Stock TitanVoyager Acquisition (NASDAQ: VACH) inks $27.5M note and $50M Veraxa share dealVeraxa Biotech Holding AG (PubCo), the entity resulting from the planned de-SPAC merger between Veraxa Biotech AG and Voyager Acquisition Corp., entered into a $27.5 million senior secured note financing and a $50 million share purchase agreement with Lincoln Park Capital Fund on May 27, 2026. The note carries 15-month maturity with $2.75 million monthly amortization, while the equity facility allows Veraxa to sell shares over 24 months at prevailing market prices minus a 3% discount, with Lincoln Park receiving $750,000 in commitment shares. The proceeds are intended to fund working capital, general corporate purposes, and support the closing of the business combination that will result in Veraxa listing on the Nasdaq Capital Market.BioSpaceVERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase AgreementVERAXA Biotech announced a $27.5 million senior secured note and a $50 million share purchase agreement to support its business combination with Voyager Acquisition Corp. The financing will fund its pipeline of BiTAC-TCE and BiTAC-ADC programs and is expected to be listed on NASDAQ.startupticker.chBiotech companies Veraxa and Curatis strengthen financial positionsVeraxa Biotech AG has secured USD 27.5 million through a senior secured convertible note with High Trail Capital LP and entered into a share purchase agreement for up to USD 50 million with Lincoln Park Capital Fund, as it prepares for a NASDAQ listing via a strategic merger with Voyager Acquisition Corp. Separately, Curatis Holding AG closed a CHF 3.0 million convertible instrument private placement with a Swiss investor to fund Phase III trials for its lead candidate corticorelin, including clinical material manufacturing for Japanese and global studies.The Streetwise ReportsCleantech Co. Wins PFAS Deal Engineering Pact Ships ClyraBioLargo reported Q1 2026 revenues of $1.1 million, down from $3.3 million a year earlier, and a net loss of $3.4 million. The company shipped Clyra's first stocking order, signed a PFAS MOU with Aquatech, and won a $1.2 million engineering contract for a minerals processing facility. Analysts reaffirmed a Buy rating with a $0.32 price target.GlobeNewswireVaxart Provides Business Update and Reports First Quarter 2026 Financial ResultsVaxart reported Q1 2026 revenue of $39.2 million and net income of $5.2 million, up from a $15.6 million loss in Q1 2025. Cash and equivalents totaled $61.0 million, with runway into Q2 2027. The company anticipates topline data from its 400-person Phase 2b COVID-19 sentinel cohort in Q2 2026.BioSpaceVaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park CapitalVaxart entered a share purchase agreement with Lincoln Park Capital to sell up to $25 million of common stock over 24 months. The company retains full discretion over timing and amount, with no price caps, and Lincoln Park agreed not to short sell or hedge. The shares are issued under securities law exemptions.GlobeNewswireDaré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLCDaré Bioscience entered a $15 million common stock purchase agreement with Lincoln Park Capital Fund, allowing the company to sell up to $15 million of its stock over 24 months. Proceeds may fund development of Sildenafil Cream, 3.6%, with a Phase 3 study estimated at $15 million. The agreement includes registration rights and no short-selling restrictions.